Immune modulation for cancer therapy

Jarushka Naidoo, D. B. Page, J. D. Wolchok

Research output: Contribution to journalArticle

Abstract

Background:Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4).Methods:Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment.Results:As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types.Conclusions:This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.

Original languageEnglish (US)
Pages (from-to)2214-2219
Number of pages6
JournalBritish Journal of Cancer
Volume111
Issue number12
DOIs
StatePublished - Dec 9 2014
Externally publishedYes

Fingerprint

Antibodies
Neoplasms
CTLA-4 Antigen
Disease Eradication
Ligands
T-Lymphocytes
Blocking Antibodies
Proxy
Therapeutics
Immune System
Melanoma
Pharmaceutical Preparations
ipilimumab

Keywords

  • anti-CTLA4
  • anti-PD-1
  • anti-PD-L1
  • BMS-936559
  • immunotherapy
  • MPDL3280A
  • nivolumab
  • tremelimumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Immune modulation for cancer therapy. / Naidoo, Jarushka; Page, D. B.; Wolchok, J. D.

In: British Journal of Cancer, Vol. 111, No. 12, 09.12.2014, p. 2214-2219.

Research output: Contribution to journalArticle

Naidoo, Jarushka ; Page, D. B. ; Wolchok, J. D. / Immune modulation for cancer therapy. In: British Journal of Cancer. 2014 ; Vol. 111, No. 12. pp. 2214-2219.
@article{2d36c30759d7458b94bdb15cfa3b683e,
title = "Immune modulation for cancer therapy",
abstract = "Background:Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4).Methods:Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment.Results:As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types.Conclusions:This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.",
keywords = "anti-CTLA4, anti-PD-1, anti-PD-L1, BMS-936559, immunotherapy, MPDL3280A, nivolumab, tremelimumab",
author = "Jarushka Naidoo and Page, {D. B.} and Wolchok, {J. D.}",
year = "2014",
month = "12",
day = "9",
doi = "10.1038/bjc.2014.348",
language = "English (US)",
volume = "111",
pages = "2214--2219",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Immune modulation for cancer therapy

AU - Naidoo, Jarushka

AU - Page, D. B.

AU - Wolchok, J. D.

PY - 2014/12/9

Y1 - 2014/12/9

N2 - Background:Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4).Methods:Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment.Results:As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types.Conclusions:This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.

AB - Background:Immune modulation in cancer refers to a range of treatments aimed at harnessing a patient's immune system to achieve tumour control, stabilisation, and potential eradication of disease. A novel therapeutic drug class called immune checkpoint-blocking antibodies modulate T-cell pathways that regulate T cells and have the potential to reinvigorate an antitumour immune response. Ipilimumab was the first FDA-approved immune checkpoint antibody licensed for the treatment of metastatic melanoma (MM) and blocks a checkpoint molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4).Methods:Herein we review the preclinical and clinical development of ipilimumab. We outline the mode of action of these agents and other immune checkpoint inhibitors, the management of their toxicities, and how to adequately assess response to treatment.Results:As a result of these data, a number of other antibodies that block novel checkpoint molecules including programmed death-1 (PD-1), and corresponding ligands such as programmed death ligand-1 (PD-L1) are under preclinical and clinical development, and have demonstrated activity in multiple tumour types.Conclusions:This review will summarise the mechanism of action and clinical development of immune checkpoint antibodies, as well as lessons learned in the management and assessment of patients receiving these agents.

KW - anti-CTLA4

KW - anti-PD-1

KW - anti-PD-L1

KW - BMS-936559

KW - immunotherapy

KW - MPDL3280A

KW - nivolumab

KW - tremelimumab

UR - http://www.scopus.com/inward/record.url?scp=84927574518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927574518&partnerID=8YFLogxK

U2 - 10.1038/bjc.2014.348

DO - 10.1038/bjc.2014.348

M3 - Article

C2 - 25211661

AN - SCOPUS:84927574518

VL - 111

SP - 2214

EP - 2219

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -